Treatment of Kawasaki Disease
Diagnosis
- The American Academy of Family Physicians recommends diagnosis based on fever for at least 5 days plus 4 or more clinical features, including bilateral non-purulent conjunctival injection, oral mucosal changes, polymorphous rash, swelling or redness of extremities, and cervical lymphadenopathy 1, 2
- Incomplete Kawasaki disease can be diagnosed with fewer criteria if coronary artery abnormalities are present on echocardiography, as recommended by the American Heart Association 1, 3
- For patients with fever >5 days and only 2-3 classic symptoms, laboratory testing should include CRP and ESR, as suggested by the American Academy of Family Physicians 1
Initial Treatment Protocol
- The American Heart Association recommends IVIG administration at a dose of 2 g/kg as a single infusion, combined with high-dose aspirin (80-100 mg/kg/day divided into four doses) until the patient is afebrile for at least 48 hours 1, 3, 4
- The initial high-dose aspirin should be continued until the patient is afebrile for at least 48 hours, then transitioned to low-dose aspirin (3-5 mg/kg/day) as a single daily dose, as recommended by the American Heart Association 3, 5
- Annual influenza vaccination is recommended for children on long-term aspirin therapy, as suggested by the American Heart Association 3, 5, 4
Management of IVIG-Resistant Disease
- Approximately 10-20% of patients develop recrudescent or persistent fever at least 36 hours after IVIG infusion, and options for IVIG-resistant cases include a second dose of IVIG, infliximab, or corticosteroids, as recommended by the American Heart Association 6, 7, 8
- A second dose of IVIG (2 g/kg as a single infusion) should be considered as the first option for IVIG resistance, as suggested by the American Heart Association 8
Long-term Antiplatelet/Anticoagulation Management
- The American Heart Association recommends long-term low-dose aspirin indefinitely for patients with small coronary aneurysms, and aspirin plus a second antiplatelet agent for patients with moderate-sized aneurysms (4-6 mm) 9, 5
- For patients with giant aneurysms (≥8 mm), the American Heart Association recommends low-dose aspirin plus warfarin (target INR 2.0-3.0) or aspirin plus therapeutic doses of low-molecular-weight heparin for infants or children where warfarin is difficult to regulate 9, 5
Monitoring
- Frequent echocardiography and ECG evaluation during the first 3 months after diagnosis are recommended, especially for patients with giant coronary aneurysms, as suggested by the American Heart Association 9
- The highest risk for coronary artery thrombosis occurs within the first 3 months, with peak incidence in the first 15-45 days, as reported by the American Heart Association 9
Common Pitfalls and Caveats
- Delaying treatment beyond 10 days increases the risk of coronary artery abnormalities, as warned by the American Heart Association 4
- Incomplete Kawasaki disease is more common in children under 1 year, who paradoxically have higher rates of coronary aneurysms if not treated, as noted by the American Academy of Family Physicians 3
- Measles and varicella immunizations should be deferred for 11 months after high-dose IVIG administration, as recommended by the American Heart Association 4
Treatment of Kawasaki Disease
Initial Treatment Protocol
- The American Heart Association recommends IVIG should be administered as early as possible within the first 10 days of fever onset, as this significantly reduces the risk of coronary artery abnormalities 10, 11
- The American Heart Association suggests high-dose aspirin (80-100 mg/kg/day divided into four doses) should be given concurrently with IVIG and continued until the patient is afebrile for 48-72 hours 11
- After fever resolution, aspirin should be reduced to low-dose (3-5 mg/kg/day as a single daily dose) and continued until 6-8 weeks after disease onset if no coronary abnormalities are present, as recommended by the American College of Cardiology 12
- For children who develop coronary abnormalities, aspirin may be continued indefinitely, according to the American College of Cardiology 12
Management of IVIG-Resistant Disease
- Approximately 10-20% of patients fail to respond to initial IVIG therapy, defined as persistent or recrudescent fever 36 hours after completion of the initial IVIG infusion, and options include a second dose of IVIG (2 g/kg as a single infusion) as the first-line treatment for IVIG resistance 13
- Corticosteroids should be considered for patients who remain febrile after two doses of IVIG, as suggested by the American Heart Association 13, 14
- The RAISE study protocol (intravenous prednisolone 2 mg/kg/day for 5 days followed by an oral taper) has shown efficacy in high-risk patients identified by scoring systems, according to the American College of Cardiology 14
- Infliximab (a TNF-α inhibitor) has shown effectiveness in treating IVIG-resistant cases, as reported by the American Heart Association 14
Special Considerations
- Measles, mumps, and varicella immunizations should be deferred for 11 months after receiving high-dose IVIG, as recommended by the American Academy of Pediatrics 11
- Annual influenza vaccination is recommended for children on long-term aspirin therapy, according to the American Academy of Pediatrics 12
- Ibuprofen should be avoided in children taking aspirin for its antiplatelet effects as it antagonizes the irreversible platelet inhibition induced by aspirin, as suggested by the American Heart Association 12
Common Pitfalls and Caveats
- Incomplete Kawasaki disease (fever plus fewer than 4 classic criteria) should still be treated if there is evidence of coronary artery abnormalities or elevated inflammatory markers, as recommended by the American College of Cardiology 10
Management of Kawasaki Disease
Treatment of IVIG-Resistant Disease
- The American Heart Association recommends administering a second dose of IVIG 2 g/kg as a single infusion for IVIG-resistant disease, which occurs in 10-20% of patients 15
- For patients with persistent fever after a second IVIG infusion, the American College of Cardiology suggests using methylprednisolone 20-30 mg/kg IV for 3 days or infliximab 5 mg/kg IV over 2 hours as second-line options, with both showing similar efficacy 16, 15
- Cyclosporine 4-6 mg/kg/day orally can be used as a third-line treatment for highly refractory cases, with monitoring for hyperkalemia, which occurred in 32% of patients in trials 15, 16
- Plasma exchange can be reserved for patients failing all medical therapies due to significant risks 16, 17
Outpatient Management and Follow-up
- For patients with moderate coronary aneurysms (4-6 mm), the American Heart Association recommends low-dose aspirin plus a second antiplatelet agent, such as clopidogrel 1 mg/kg/day, max 75 mg/day 18
- For patients with giant aneurysms (≥8 mm), the American College of Cardiology suggests low-dose aspirin plus warfarin, with a target INR of 2.0-2.5, which reduces the risk of myocardial infarction significantly 18, 19
- Regular physical activity should be encouraged within parameters defined by ischemia/arrhythmia risk, with written guidance on activity restrictions to prevent unnecessary inactivity 19
Role of Steroids in Kawasaki Disease
Primary Treatment in High-Risk Patients
- For high-risk patients predicted to be IVIG-resistant, adding corticosteroids to initial IVIG and aspirin therapy significantly reduces coronary artery aneurysms and should be strongly considered, though risk stratification tools perform poorly in non-Japanese populations 20
- Multiple Japanese trials using different steroid regimens consistently showed lower rates of coronary abnormalities and treatment resistance in high-risk patients 20
- The major caveat is that Japanese risk-stratification scores have low sensitivity in North American and European populations, making it difficult to identify which patients would benefit from primary steroid therapy 20
Treatment of IVIG-Resistant Disease
- Corticosteroids should be used for patients who remain febrile after two doses of IVIG have failed to control fever and inflammation 21, 22
- The American Heart Association recommends corticosteroid therapy, most commonly IV pulse methylprednisolone 30 mg/kg for 2-3 hours daily for 1-3 days, for patients failing two IVIG infusions 21, 22
- Infliximab is an equally effective alternative to steroids for IVIG-resistant disease, with similar efficacy 20
- Corticosteroids consistently reduce fever duration and inflammatory markers in IVIG-resistant patients 21, 22
Practical Steroid Regimens
- The RAISE protocol involves prednisolone 2 mg/kg/day IV for 5 days, then oral taper over weeks, combined with IVIG 2 g/kg and aspirin 30 mg/kg/day 20
- Pulse methylprednisolone can be used as a single dose or for 1-3 days 20
- The standard regimen for IVIG-resistant disease is methylprednisolone 30 mg/kg IV over 2-3 hours daily for 1-3 days 21, 22